Immunotherapy before Chemo-Radiation shows promise for Hard-to-Treat cancers
NCT ID NCT04165772
First seen Jan 24, 2026 · Last updated Jun 21, 2026 · Updated 27 times
Summary
This phase II trial is testing whether giving the PD-1 blocker TSR-042 (dostarlimab) before standard chemoradiation and surgery can improve outcomes for people with advanced mismatch repair deficient (dMMR) solid tumors. The study will enroll 212 adults with locally advanced rectal cancer or other dMMR tumors. The main goal is to see how many patients have a complete response (no cancer detectable) after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Baptist Alliance MCI (Data Collection Only)
RECRUITINGMiami, Florida, 33143, United States
Contact Phone: •••-•••-••••
-
Hartford Healthcare (Data Collection)
RECRUITINGHartford, Connecticut, 06102, United States
Contact Phone: •••-•••-••••
-
Lehigh Valley Health Network (Data Collection Only)
RECRUITINGAllentown, Pennsylvania, 18103, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Bergen - Limited Protocol Activities
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Commack - Limited Protocol Activities
RECRUITINGCommack, New York, 11725, United States
Contact
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth - Limited Protocol Activities
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau - Limited Protocol Activities
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester - Limited Protocol Activities
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dostarlimab (TSR-042) plus capecitabine or 5-FU chemotherapy and radiation therapy
What this could lead to
If successful, this could offer a way to shrink or eliminate advanced dMMR tumors before surgery, potentially reducing the need for more aggressive treatments.
What could go wrong
This is a mid-stage trial with a moderate number of participants. The combination of immunotherapy, chemotherapy, and radiation may cause significant side effects, and not all patients may respond.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.